Day: September 8, 2020

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM) (“Wallbridge” or the “Company”) is pleased to report that initial drilling on the new ground acquired through its recent acquisition of Balmoral Resources Ltd. (“Balmoral”) has greatly expanded the ultimate size potential of the Fenelon Gold System.Recent drilling has extended gold mineralization 500 metres to the west and 850 metres to the south of Area 51. This greatly expands the ultimate potential size of the Area 51 vein network gold mineralization on Wallbridge’s 100%-owned Fenelon Gold Property (“Fenelon” or the “Property”). The Area 51 vein network, along with the Tabasco, Cayenne and Gabbro Zones, form parts of a large gold system (“Fenelon Gold System”) located within and adjacent to the Jeremie Diorite, which has now been traced for...

Acquisition aligns with strategy for accretive acquisition and extends product offerings in DevOps and DevSecOps with market-leading infrastructure automationBEDFORD, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Progress (NASDAQ: PRGS), the leading provider of application development and digital experience technologies, today announced that it has entered into a definitive agreement to acquire Chef, a global leader in DevOps and DevSecOps, providing complete infrastructure automation to build, deploy, manage and secure applications in modern multi-cloud and hybrid environments, as well as on-premises.    “Chef is a market leader with best-in-class products, a vibrant developer community, an impressive blue-chip customer base and highly skilled and engaged employees,” said Yogesh Gupta, CEO, Progress. “Chef has built a successful business,...

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the U.S. Food and Drug Administration (“FDA” or “the Agency”) has granted approval for the company to proceed with a pivotal study of the CGuard™ Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States. “This is a key milestone in the history of our company as it helps pave the way for us to initiate a clinical trial of CGuard EPS for addressing Carotid Artery Disease and preventing stroke in the United States market. This will be the first U.S.-based study of CGuard which is a cornerstone of our global expansion plans,” said Marvin Slosman, InspireMD’s CEO. “A...

~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Resulted in a Loss of Cortisol Response in 54.5 Percent (p=0.0002) More Patients than the RECORLEV® (levoketoconazole) Arm ~~ RECORLEV® (levoketoconazole) was Generally Well Tolerated with a Safety and Tolerability Profile Comparable to the Profile Observed in the Phase 3 SONICS Study ~~ Company Anticipates Submitting a New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021; If Approved, Expects to Launch RECORLEV in the First Quarter of 2022 ~~ Company to Host Conference Call Today at 8:30 a.m. ET ~DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq:...

VANCOUVER, British Columbia, Sept. 08, 2020 (GLOBE NEWSWIRE) — MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG Silver”) is pleased to announce that the US$50 million at-the-market equity program (the “ATM Program”) previously announced (see Press Release June 30, 2020) has been completed.  Since June 30, 2020, MAG Silver sold and issued 3,092,783 common shares under the ATM Program at an average price of US$16.16 per share, for gross and net proceeds of US$50 million and US$48.625 million, respectively. There is no further remaining availability under this ATM Program.Under the ATM Program, MAG Silver was permitted to issue up to an aggregate of US$50 million worth of common shares from treasury, at prevailing market prices to the public through the NYSE American or any other marketplace on which the common shares are listed,...

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccinesNEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech SE (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.All nine CEOs signed the following pledge:We, the undersigned biopharmaceutical companies,...

HANGZHOU, China, Sept. 08, 2020 (GLOBE NEWSWIRE) — Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), a leading high-performance computing solutions provider, today announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$10 million worth of its outstanding (i) American depositary shares (“ADSs”), each representing 15 Class A ordinary shares, and/or (ii) Class A ordinary shares over the next 12 months starting from September 22, 2020.Under the share repurchase program, the Company may repurchase its ADSs from time to time through open market transactions at prevailing market prices, privately negotiated transactions, block trades or any combination thereof. In addition, Canaan will also effect repurchase transactions in compliance...

-Highly statistically significant reductions in both pruritus and serum bile acids--Well tolerated with very low incidence of diarrhea--Similar efficacy in children with PFIC1 or PFIC2--Pivotal trial results substantiate potential for odevixibat to be first drug for PFIC patients-–Regulatory submissions for approval on track–-Conference call to be held today at 8:30 a.m. EDT-BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced positive topline results from PEDFIC 1, a global Phase 3 clinical trial evaluating the efficacy and safety of odevixibat and the largest study ever conducted in PFIC1 and PFIC2. PEDFIC 1 met its two primary endpoints, demonstrating that odevixibat reduced serum...

NEWPORT BEACH, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company (“DPW,” or the “Company”) announced that construction is fully underway on the Tribeca Hotel at 456 Greenwich Street, New York, NY. The foundation has been completed and the superstructure has emerged from the ground. The opening date of the luxury hotel is slated for the summer of 2022. The Company is a limited partner in the Tribeca Hotel development project (the “NY Partnership”).Background on the NY PartnershipOn June 8, 2018, the Company entered into a limited partnership agreement, in which it agreed to become a limited partner in the NY Partnership and has invested an aggregate of $1,869,000. On June 12, 2019, the agreement was restructured whereby DPW has no further funding obligations until the...

Municipality Finance PlcStock exchange release8 September 2020 at 1:30 pm (EET)Municipality Finance issues its debut social bond under MTN programmeMunicipality Finance Plc issues EUR 500 million social bond on 10 September 2020. The maturity date is 10 September 2035. The social bond bears interest at fixed rate of 0.050 % per annum.The social bond is issued under MuniFin’s EUR 40 billion programme for the issuance of debt instruments. The offering circular is available in English on the company’s website at www.munifin.fi/investor-relations.MuniFin has applied for the social bond to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 10 September 2020.BNP Paribas, Credit Agricole CIB, DZ Bank and SEB act as the Joint Lead Managers for the issue of the...